News About: Pharm. Affairs
‘Pradaxa 75mg’ approval voluntarily withdrawn due to insufficient usage
Boehringer Ingelheim was confirmed to voluntarily withdraw Korean approval of the low volume of its novel oral anticoagulant, ‘Pradaxa(generic name: dabigatran).’ It has been a year since it acquired the approval on A...
‘Kanarb’ shows off in front of circulatory system experts around the world
A Korean new drug Kanarb in the hypertension market is challenging to the global market beyond the Korean market. The drug is expected to be called the first Korean global drug recognized by both of the Korean and for...
Is GSK preparing to launch migraine drugs? The company refused it
While there was a rumor about transfer of antihypertensive ‘Pritor’ license not long ago, people concerned to the industry made an anticipation that GSK soon will launch a pain killer, Panadol or Excedrin. The company...
Advanced logistics service being changed in Korea and foreign countries, ‘Cold Chain’
While pharmaceutical logistics has become more important in the world, biomedicines that are sensitive to temperature have made a new trend by periodically enlarging their field in the international pharmaceutical mar...
Blincyto registered with KRW 2.48 million
An acute lymphoblastic leukemia treatment, Blincyto(blinatumomab) and a cell treatment for burn, Keraheal-Allo(cultured allogenic keratinocytes, kaloderm) will be newly registered in the drug insurance benefit list.
...
Sovaldi dispensing avoided in pharmacy circles worrying about excessive taxes
Sovaldi and Harvoni as hepatitis C treatment have recently been sharply increased.
However, avoidance on the drugs due to dispensing prices that are relatively lower than actual drug prices has been intensified in th...
HIRA decides Keytruda & Opdivo’s insurance benefits with anti-PD-L1 TPS
‘Tumor proportion score(TPS) of anti-PD-L1’ is set as an index to decide whether to accept the insurance benefits of immunotherapies to treat non-small cell lung cancer.
The health insurance benefits of MSD’s ‘Keytr...
Announcement of Glyxambi launch popularizes Jardiance & Trajenta
As it was recently known a Boehringer Ingelheim diabetes treatment combined by DPP-4 and SGLT-2 inhibitors, ‘Glyxambi’ applied for commercialization approval from the Ministry of Food and Drug Safety(MFDS), ‘Trajenta(...
Reason why there are different viewpoints on overall approval of ‘phentermine’
After the Ministry of Food and Drug Safety(MFDS), last October, announced a direction to newly approve drugs containing phentermine and phendimetrazine at the end of 2017, various opinions have been crossed.
Among th...
Changing trend of cold medicines to spraying type
The dosage form of cold medicines is changing from tablet to spray. Their indication is also shifting from nose to throat.
In fact, there even was no market for spraying-type sore throat treatments.
As launching Bet...
